AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03192670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level light therapy device
Description: Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
Study NCT03192670 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low-level light therapy device
Description: Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
Study NCT00737204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
Study NCT00737204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
Study NCT01233960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adult human mesenchymal stem cells
Description: PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
Study NCT05839782 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve repair (PLM)
Description: A mitral valve plasty is performed to treat mitral regurgitation
Study NCT01680302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Study NCT05839782 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve replacement
Description: A mitral valve replacement with a prosthesis is performed to treat mitral regurgitation
Study NCT00688701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT01680302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Study NCT00688701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00688701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00688701 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study NCT03777332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGCETACOPLAN (APL-2)
Description: Complement (C3) Inhibitor
Study NCT02319174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sphygmo
Description: A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
Study NCT04068129 — intervention group
Intervention type: DEVICE
Intervention: photoscreen
Description: Determine amblyopia risk factors
Study NCT01680302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Advised to follow current guidelines for physical activity, but exercise on their own.
Study NCT00829647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib and lenalidomide
Description: dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
Study NCT02110225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 60 µg/ml eye drops solution
Description: rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
Study NCT02110225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 180 µg/ml eye drops solution
Description: rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
Study NCT02110225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
Study NCT03967093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
Study NCT01095601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avanafil
Description: * Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~* Treatment B: 2x100 mg Formulation II avanafil tablet, fed~* Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~* Treatment D: 1x50 mg Formulation II avanafil tablet, fasted
Study NCT02068352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Description: OPA-15406 topical ointment
Study NCT02068352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: OPA-15406 1%-matching placebo topical ointment
Study NCT02157688 — intervention group
Intervention type: OTHER
Intervention: no intervention : case control study
Study NCT02096757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega
Description: Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
Study NCT02096757 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pro-Omega Placebo
Description: Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
Study NCT03793673 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CoYoT1 Care
Description: Selected providers will be trained in the CoYoT1 Care protocol for completing medical appointments (both telehealth/standard appointments). There are three key components: (1) Shared decision making: Providers and YA will mutually agree on priorities for each medical visit using a shared decision making tool completed by both the provider and patient. (2) Autonomy supportive care: Providers will be trained in communication strategies, such as motivational interviewing, designed to support YA autonomy and intrinsic motivation. YA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach YA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate.
Study NCT03793673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Providers selected for the Standard Care group will complete medical appointments in their usual manner, without specific training or guidelines regarding how to deliver care.~NOTE: Per COVID-19 hospital policies, current clinic appointments consist of telehealth appointments.
Study NCT04210908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual biofeedback
Description: Patient will observe the descent of the fetal head as they push during contractions
Study NCT03722953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation
Study NCT03722953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic Exercise
Description: 1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation
Study NCT03989206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab
Study NCT01182597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole (Pantoloc)
Description: Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs
Study NCT01182597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole (Takepron OD)
Description: Lansoprazole (Takepron OD) 30mg q12h PO
Study NCT03875274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine, Morphine
Description: Morphine added to ropivacaine for fascia iliaca compartment block
Study NCT03875274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine, Saline
Description: Normal saline added to ropivacaine for fascia iliaca compartment block
Study NCT02607345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zusto
Description: 25gr
Study NCT02607345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucomedics®
Description: 25gr
Study NCT00292305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Implantation of coronary stent in bifurcation lesions
Study NCT00292305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Implantation of coronary stent in bifurcation lesions
Study NCT01659177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study NCT01968083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV cps2 Vaccine
Description: 10\^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
Study NCT01968083 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
Study NCT01083420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 0.2% mouthwash
Study NCT01083420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.01% mouthwash
Study NCT01566305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buttermilk without added egg-yolk
Description: Buttermilk without added egg-yolk
Study NCT01566305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buttermilk with added egg yolk
Description: Buttermilk with added egg yolk
Study NCT01566305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skimmed milk with added egg-yolk
Description: Skimmed milk with added egg-yolk
Study NCT01566305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Skimmed milk without added egg yolk
Description: Skimmed milk without added egg yolk
Study NCT00251927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40 mg oral tablet administered daily
Study NCT00251927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic fundoplication (surgery)
Description: Surgery
Study NCT02111226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS text messaging
Description: short message service
Study NCT02111226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS text messaging
Description: short message service
Study NCT01205321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bombesin (68Ga) labeled (BAY86-7548)
Description: Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
Study NCT01205321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bombesin (68Ga) labeled (BAY86-7548)
Description: Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
Study NCT01393080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and TP regimen
Description: 1. TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression.
Study NCT01393080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TP regimen
Description: TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
Study NCT01077726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Study NCT03122730 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VentaProst
Description: Part I - an equivalent dose of VentaProst compared to conventionally-administered aerosolized epoprostenol with subsequent dose titration to achieve a clinically significant hemodynamic response Part II - Dose titration to achieve a clinically significant hemodynamic response.
Study NCT01850368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy.
Study NCT01454453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients- dose titration
Description: dose titration (patients) - 4-10 weeks
Study NCT02019134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation exercise
Description: relaxation exercise
Study NCT02019134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ususal care
Study NCT01373996 — intervention group
Intervention type: DEVICE
Intervention: Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)
Description: The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.~A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System.
Study NCT04176159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOTOR IMAGERY AND TASK-ORIENTED TRAINING
Description: The intervention will be divided into two modules. A first module will include activities of activation and relaxation of the body, prediction and sequencing of movement and motor imagery. The second module, task-oriented training, will be divided into analytical work phase (visual coordination, balance, muscular strength, fine motor skills ...), a second phase of integration into specific tasks and, at end, the inclusion of the free (and supervised) practice of a sport.~The investigators will apply 20 sessions of 40 minutes.
Study NCT00079456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00079456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00079456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03604757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-617 PET/CT
Description: PET/CT Imaging with 68Ga-PSMA-617 injection
Study NCT03604757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2 PET/CT
Description: PET/CT Imaging with 68Ga-RM2 injection
Study NCT02117934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV
Description: Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
Study NCT02117934 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injections at Week 0, Week 4, and Week 24
Study NCT01503840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
Study NCT01503840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride solution
Description: Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
Study NCT00974701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam ESO2
Description: The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
Study NCT00517075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Study NCT00517075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Study NCT00517075 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Study NCT00517075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
Study NCT02676752 — intervention group
Intervention type: PROCEDURE
Intervention: Medical Examination
Description: Evaluation of secondary lymphedema and fibrosis (LEF) status
Study NCT02676752 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Completion of questionnaires
Study NCT02676752 — intervention group
Intervention type: PROCEDURE
Intervention: Shear Wave Elastography
Description: Undergo ultrasound shear wave elastrography
Study NCT03456167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecoverWell mobile app for follow-up care
Description: The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
Study NCT00390455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT00390455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Given IM
Study NCT00390455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00390455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00390455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT00390455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO